Figure 6—figure supplement 1.

(A) Representative traces of waking activity after Aβ^long versus Aβ^rev injections in wild type larvae in the absence (left) or presence (right) of the Aβ-Prp binding disruptor, Chicago Sky Blue 6B (3 nM). The data are from the same injections as in Figure 6B. Ribbons represent ± SEM. Light and dark bars indicate the lights ON and lights OFF periods, respectively. (B) The change in normalized waking activity induced by Aβ^long versus Aβ^rev control injections in the absence or presence of 3 nM Chicago Sky Blue 6B. Each dot represents a single larva and error bars indicate ± SEM. The mean difference effect size and 95% confidence interval is plotted at the bottom. N = the number of larvae in each group. **p≤0.01, Kruskal-Wallis, Tukey-Kramer post hoc. (C) Representative traces of sleep behavior after Aβ^long versus Aβ^rev injections (left) in the presence of the mGluR5 inhibitor, MPEP (5 μM) and (right) Src-kinase inhibitor, saracatinib (300 nM). Ribbons represent ± SEM. The data are from the same injections as in Figure 6D. (D) The change in sleep induced by Aβ^long relative to Aβ^rev control injections in the presence of MPEP (5 μM) and (300 nM) saracatinib. *p≤0.05, **p≤0.01, Kruskal-Wallis, Tukey-Kramer post hoc.